诱导化疗序贯尼妥珠单抗和放疗同步治疗局部晚期鼻咽癌患者的临床观察

Clinical Observation of Induction Chemotherapy Followed by Nimotuzumab and Radiotherapy in the Treatment of Patients with Locally Advanced Nasopharyngeal Carcinoma

摘要: 目的：评价诱导化疗联合尼妥珠单抗注射液联合放疗治疗局部晚期鼻咽癌的疗效和副反应。方法：收集2019年1月至2021年1月烟台毓璜顶医院收治的31例局部晚期鼻咽癌患者，先行TP方案(紫杉醇 + 顺铂)化疗2周期，然后同步尼妥珠单抗联合放疗。评估患者的治疗疗效、客观缓解率(overall response rate, ORR)、疾病控制率(disease control rate, DCR)、无进展生存期(progression free survival, PFS)、总生存期(overall survival, OS)和不良反应发生情况。结果：随访12~36个月，中位随访时间为24个月。所有患者的ORR为80.65% (25/31)，DCR为100%；治疗相关不良反应发生率为93.55% (29/31)；不良反应以1~2级为主，≥3级不良反应发生率为12.9% (4/31)；随访期间，无患者死亡。结论：诱导化疗联合尼妥珠单抗注射液联合放疗治疗为局部晚期鼻咽癌患者的综合治疗提供了有益的尝试，安全性好，改善患者的生存质量。

Abstract: Objective: To evaluate the efficacy and side effects of induction chemotherapy followed by nimotuzumab injection combined with radiotherapy in the treatment of locally advanced nasopharyngeal carcinoma. Methods: A collection of 31 patients with locally advanced nasopharyngeal carcinoma admitted to Yantai Yuhuangding Hospital from January 2019 to January 2021 were treated with TP regimen (paclitaxel + cisplatin) for 2 cycles of chemotherapy, and then concurrent nimotuzumab combined with radiotherapy was enrolled in the study. The patient’s treatment efficacy, overall response rate (ORR), disease control rate (DCR), progression free survival (PFS), overall survival (OS) and adverse effects were evaluated. Results: The follow-up period was 12~36 months, and the median follow-up time was 24 months. The ORR of all patients was 80.65% (25/31), and the DCR was 100%; the incidence of treatment-related adverse reactions was 93.55% (29/31), and the main adverse reactions were grade 1~2, the incidence of grade ≥ 3 adverse reactions was 12.9% (4/31); during the follow-up period, no patients died. Conclusions: Induction chemotherapy followed by nimotuzumab injection combined with radiotherapy provides a useful attempt for comprehensive treatment of patients with locally advanced nasopharyngeal carcinoma, which is safe and improves the quality of life of patients.